Isembyld™
Understanding Isembyld™
Isembyld™ (apitegromab-mstn) is a prescription medicine indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. Isembyld™ is a recombinant monoclonal antibody targeting proforms of myostatin and is administered by intravenous infusion.
How Isembyld™ Works:
- Targets proforms of myostatin: Isembyld™ contains apitegromab-mstn, a recombinant monoclonal antibody targeting proforms of myostatin.
- Acts on the myostatin pathway: Apitegromab-mstn targets proforms of myostatin.
FDA Approval:
Isembyld™ (apitegromab-mstn) received its initial U.S. FDA approval in 2026 for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.
For more information, please visit the Isembyld™patient website. Speak with your healthcare provider to determine if Isembyld™ is the right treatment option for you.
Referral Form: |
WHAT IT TREATS: |
MANUFACTURER: Scholar Rock, Inc.
|
CLASS: Recombinant monoclonal antibody targeting proforms of myostatin |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: Intravenous (IV) infusion |
|
FREQUENCY: Once every 4 weeks |
Length of infusion: Approximately 60 to 120 minutes |
FOR MORE INFORMATION: |
